ArticleParasites & vectors2026
Recombinant Echinococcus granulosus myophilin alleviates airway inflammation in mice with ovalbumin-induced allergic asthma via the gut microbiota-metabolite-immune axis.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundParasitic infections or their secreted components exhibit therapeutic effects against certain allergic diseases. Allergic asthma is a chronic inflammatory airway disease with potentially severe symptoms and increasing prevalence worldwide. Recombinant Echinococcus granulosus myophilin (rEg.myophilin) induces a Th1 immune response in mouse spleens; however, the effects and mechanisms of rEg.myophilin in allergic asthma remain unclear.
methodsWe investigated the anti-inflammatory effects of rEg.myophilin on airway inflammation in mice with ovalbumin (OVA)-induced allergic asthma through histopathology, flow cytometry, and enzyme-linked immunosorbent assay. 16S rRNA sequencing and non-targeted metabolomics of mouse fecal samples and correlation analyses of microbiota, metabolites, and inflammatory indicators were used to explore the mechanistic role of rEg.myophilin in allergic asthma.
resultsrEg.myophilin significantly ameliorated OVA-induced allergic airway inflammation. Pathological findings revealed a marked reduction in lung inflammatory cell infiltration, collagen deposition, and mucus secretion. rEg.myophilin also corrected the imbalance in Th1/Th2 cell ratios in lung tissues and reduced the abundance of Tenericutes and Candidatus_Arthromitus. Among the 19 metabolites with significant differences among Con, OVA, and OVA+rEg.myophilin groups, those linked to linoleic acid metabolism, indicating that rEg.myophilin may act through the linoleic acid metabolic pathway to alleviate allergic asthma. Spearman's correlation analysis revealed positive/negative correlations between several differential metabolites, differential microbiota, and immune indicators.
conclusionsrEg.myophilin alleviates OVA-induced allergic asthma in mice by modulating interactions among intestinal microbiota, metabolites, and immune cells. This research provides theoretical insights and novel biological targets for the prevention and treatment of allergic asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.